A deal worth up to USD 5.7 billion has been unveiled that is aimed at the development of molecular glue degraders for immune-mediated diseases utilizing Monte Rosa’s AI-driven QuEEN platform.

In light of the evolving therapeutic landscape, increasing use of advanced technologies, and political shifts, regulatory updates are inevitable, meaning that bio/pharma companies will need to adjust quickly to new requirements.

Several big players within the bio/pharma industry are pulling back their investments from the United Kingdom amid fears over the security of the country’s life sciences environment.

In this guest blog post, Will Downie and Elliott Berger delve into the key factors that are negatively impacting CDMO revenue performance and highlight the foundational elements that should be adopted to ensure success.

The companies have joined forces to launch an advanced lipid nanoparticle platform for RNA medicine delivery to advance the next generation of gene and vaccine therapies.

The company has decided to voluntarily withdraw obeticholic acid from the U.S. market after the FDA issued a request for the withdrawal and put a clinical hold on trials involving the drug.  

The global healthcare company is expecting that its efforts to streamline operations will allow it to improve the speed of decision making and reinvest savings into pertinent growth opportunities.

The latest multi-asset licensing and option agreement between Argos and Novartis, will grant the Swiss pharma giant rights to key siRNA molecules, building on the companies’ partnership.

In a financial report webcast, the Norwegian biotech presented breakthrough circVec-AAV data showing up to 40x higher protein expression than traditional mRNA-AAVs.

Located in Hopewell, N.J., the new facility signifies the first major manufacturing investment for Enzene within the U.S., strengthening the company’s commitment to supporting innovation and supply chain resilience in the country.

Industry leaders delve into the latest biopharma supply chain disruptions and provide insights into approaches that can help to reduce vulnerabilities and ensure greater resilience in the future.

This latest funding will bolster the additional investment and private capital and will allow Delpharm to modernize its Boucherville facility to be able to meet the growing demand for injectable drugs.

As pharmaceutical packaging evolves to incorporate more patient-centric designs, overcome increasingly complex formulations, and undergo a digital transformation, safety and compliance remain non-negotiables.

With an increasing spotlight on sustainability, it is increasingly important for industry-wide sustainability practices to be implemented to ensure transformative change is achieved.

In this white paper, Chris Gilmor, Director of Sales, Sanner America, introduces the company’s new packaging platform, TabTec® CR, which is a convenient solution for oral solid dosage products with integrated desiccant and child-resistant opening.

While biomanufacturing has ample capacity, a funding downturn and workforce shortages have created a paradoxical situation, putting pressure on sponsors’ decisions when it comes to choosing their manufacturing partners.

While there have been promising advances in terms of technologies to help the development and manufacture of next-gen therapies, limitations remain; but, it is likely that AI will be revolutionary for development in the near future.

Advanced technologies, while important for the successful development and manufacture of next-gen therapies, are still a long way off being impactful, meaning more investment is needed to reap the rewards of these promising treatments.

Digital systems, automation, and flexibility are crucial for overcoming the hurdles associated with the development and manufacture of next-gen therapies, but ongoing investment is critical to ensure continued innovation in the sector.

Affordability and accessibility are critical factors for commercial success of next-gen therapies; however, greater industry collaboration is needed to reduce inefficiencies in the development of advanced technologies.